1/55
Looks like no tags are added yet.
Fentanyl (transdermal) brand name and class?
Duragesic
Class: Opioid Analgesic. C-II
Fentanyl common FDA label indication, dosing, and titration?
Pain, chronic, including cancer pain: adults and children > or = 2 y of age, opioid tolerant, with pain that cannot be managed by other means, transdermal fentanyl dosage based on the patient’s current 24-h oral morphine requirement; replace patch q 72 h; may replace patch q 48 h in patients not achieving adequate analgesia
Fentanyl (transdermal) MOA?
Fentanyl is a phenylpiperidine opioid agonist with predominant effects on the mu-opioid receptor and is about 50-100 times more potent as an analgesic than morphine.
Fentanyl (transdermal) box warnings?
Respiratory depression; addiction, CYP3A4/5 interactions, fatalities in children; formulations not interchangeable; care with disposal; REMS program; concurrent use with benzodiazepines or other CNS depressants, neonatal withdrawal, heat exposure with transdermal patch
Fentanyl (transdermal) contraindications?
Acute or postoperative pain, bronchial asthma, hypersensitivity to fentanyl, mild or intermittent pain management, opioid nontolerant patients, paralytic ileus
Fentanyl (transdermal) drug interactions?
Barbiturates, benzodiazepines, centrally acting muscle relaxants, opioids, phenothiazines → additive CNS depression → monitor and consider dose adjustments
Beta-blockers and calcium channel blockers → additive hypotension when combined with fentanyl anesthesia → avoid concurrent use
Buprenorphine, opioid mixed agonists/antagonists, opioid antagonists → precipitation of withdrawal symptoms → avoid concurrent use of opioid antagonists and opioid agonists
CYP3A4/5 inducers → increased fentanyl metabolism decreases fentanyl efficacy → consider dose increases of fentanyl
CYP3A4/5 strong/moderate inhibitors → decreased fentanyl metabolism increases risk of fentanyl toxicity → avoid concurrent use
MAOIs → additive respiratory depression → avoid concurrent use
SSRIs, SNRIs, TCAs, Triptans, linezolid → increased risk of serotonin syndrome → counsel patient on signs and symptoms of serotonin syndrome (palpitations, agitation, sweating, etc.) and to seek immediate medical attention if it develops
Fentanyl (transdermal) ADR?
Common - application site reactions, constipation, GI distress, confusion, headache, urinary retention, fatigue, edema, nausea, vomiting
Less common - anxiety, arrhythmias, chest pain, dyspnea, respiratory depression, upper respiratory tract infection, sweating
Rare but serious - stevens-johnson syndrome, physical dependence, tolerance, deafness
Folic acid brand name and class?
FA-8, True folic acid
Class: Essential B vitamin
Folic acid common FDA label indication, dosing, and titration?
Megaloblastic and macrocytic anemia due to folic acid deficiency: infants, 0.1 mg/d po; children age <4 y, up to 0.3 mg/d po; children > or = 4 y of age, 0.4-1 mg/d po; adults, 0.4-1 mg po daily
Folic acid MOA?
Folic acid is required for the conversion of deoxyuridylate to thymidylate, which is a rate-limiting step in DNA synthesis. Folic acid deficiency presents clinically as macrocytic anemia when red blood cells are unable to extrude their nucleus.
Folic acid box warnings?
None
Folic acid contraindications?
Hypersensitivity
Folic acid drug interactions?
Barbiturates → decreased folic acid absorption; increases barbiturate metabolism and less efficacy → monitor barbiturate efficacy
Phenytoin → decreased folic acid serum levels; decreased phenytoin effectiveness → monitor for seizure control
Pyrimethamine → decreased efficacy of sulfadoxine/pyrimethamine, leading to treatment failure → avoid folic acid doses > 2.5 mg/d
Folic acid ADR?
Common - loss of appetite
Less common - confusion, irritation
Rare but serious - anaphylaxis
Gabapentin brand name and class?
Neurontin, Gralise
Class: Gamma Aminobutyric Acid Analog, Anticonvulsant
Gabapentin common FDA label indication, dosing, and titration?
Partial seizure, adjunct: immediate release, adults and children > or = 12 y of age, initial, 300 mg po tid, may titrate to 1800 mg/d in 3 divided doses (max 2400-3600 mg/d); children 3-11 y of age, initial, 10-15 mg/kg/d divided in 3 doses maintenance (Children 3-4 y of age), may titrate over 3 d to 40 mg/kg/d in 3 divided doses, maintenance (Children 5-11 y of age), may titrate over 3 d to 25-35 mg/kg/d in 3 divided doses
Postherpetic neuralgia: immediate release, adults, 300 mg po on day 1, 300 mg bid on day 2, 300 mg tid on day 3, may titrate dose to 1800-3600 mg/d in 3 divided doses; ER, 300 mg on day 1, 600 mg on day 2, 900 mg days 3-6, 1200 mg days 7-10, 1500 mg days 11-14, and 1800 mg po daily thereafter
Gabapentin MOA?
Gabapentin is a cyclohexane compound that is structurally related to GABA; its mechanism of action is not known. Gabapentin does not interact with GABA receptors or alter the formation, release, degradation, or reuptake of GABA.
Gabapentin box warnings?
None
Gabapentin contraindications?
Hypersensitivity
Gabapentin drug interactions?
Antacids → decreased gabapentin absorption → separate administration by 2 hours
CNS depressants (alcohol, hypnotics, opioids) → enhance the sedative effect → advise patients to use cautiously or not at all
Gabapentin ADR?
Common - ataxia, dizziness, somnolence, fatigue
Less common - blurred vision, diarrhea, hostile behavior, peripheral edema, nausea, nystagmus, vomiting, weight gain, xerostomia
Rare but serious - Stevens’s-Johnson syndrome, suicidal thoughts
Glimepiride brand name and class?
Amaryl
Class: Second-generation Sulfonylurea, Antidiabetic
Glimepiride common FDA label indication, and dosing?
Diabetes-mellitus, type 2: 1-2 mg po daily, may titrate by 1-2 mg every 1-2 wk to effect, max dose 8 mg po daily
Glimepiride MOA?
Sulfonylureas enhance insulin secretion from pancreatic β-cells and potentiate insulin action on several extrahepatic tissues. Long-term sulfonylureas increase peripheral utilization of glucose, suppress hepatic gluconeogenesis, and possibly increase the sensitivity and/or number of peripheral insulin receptors.
Glimepiride box warnings?
None
Glimepiride contraindications?
Hypersensitivity to sulfonylureas, diabetic ketoacidosis
Glimepiride drug interactions?
Beta-blockers → altered glucose metabolism and increased risk of hypoglycemia, symptoms of hypoglycemia masked → avoid concurrent propranolol; use others with caution and increased monitoring
CYP2C9 inducers → increased glimepiride metabolism and decreased glimepiride efficacy → monitor blood glucose and consider dose increases of glimepiride
CYP2C9 inhibitors → decreased glimepiride metabolism and increased risk of glimepiride toxicity → monitor blood glucose and consider dose decreases of glimepiride
Fluoroquinolones, NSAIDs, Fenofibrate, SSRIs, somatostatin analogues → altered glucose metabolism and increased risk of hypoglycemia and hyperglycemia → avoid concurrent use if possible; monitor and consider dose adjustments
MAOIs → stimulation of insulin secretion, hypoglycemic effects → avoid concurrent use if possible; monitor and consider dose adjustments
Psyllium → psyllium may delay absorption of glucose from meals, increasing hypoglycemic effects → avoid concurrent use if possible; monitor and consider dose adjustments
Sulfonamides, GLP-1 RA, SGLT2 inhibitors, insulin → increased risk of hypoglycemia → monitor blood glucose and consider dose adjustments
Glimepride ADR?
Common - none known
Less common - hypoglycemia, nausea, headache, dizziness and asthenia, and increased LFTs
Rare but serious - cutaneous hypersensitivity, hemolytic anemia, hepatotoxicity, disulfiram interactions
Glipizide brand name and class?
Glucotrol
Class: Second-generation Sulfonylurea, Antidiabetic
Glipizide common FDA label indication, dosing, and titration?
Diabetes mellitus: immediate release, 2.5-5 mg po daily, may titrate to max 40 mg po daily, divide bid if doses > 15 mg; extended-release, 2.5-5 mg po daily, may titrate to max 20 mg po daily
Glipizide MOA?
Sulfonylureas enhance insulin secretion from pancreatic β-cells and potentiate insulin action on several extrahepatic tissues. Long-term sulfonylureas increase peripheral utilization of glucose, suppress hepatic gluconeogenesis, and possibly increase the sensitivity and/or number of peripheral insulin receptors.
Glipizide box warnings?
None
Glipizide contraindications?
Hypersensitivity to sulfonylureas, diabetic ketoacidosis, type 1 diabetes
Glipizide drug interactions?
Beta-blockers → altered glucose metabolism and increased risk of hypoglycemia, symptoms of hypoglycemia masked → avoid concurrent propranolol; use others with caution and increased monitoring
CYP2C9 inducers → increased glipizide metabolism and decreased glipizide efficacy → monitor blood glucose and consider dose increases of glipizide
CYP2C9 inhibitors → decreased glipizide metabolism and increased risk of glipizide toxicity → monitor blood glucose and consider dose decreases of glipizide
Fluoroquinolones, NSAIDs, Fenofibrate, SSRIs, somatostatin analogues → altered glucose metabolism and increased risk of hypoglycemia and hyperglycemia → avoid concurrent use if possible; monitor and consider dose adjustments
MAOIs → stimulation of insulin secretion, hypoglycemic effects → avoid concurrent use if possible; monitor and consider dose adjustments
Psyllium → psyllium may delay absorption of glucose from meals, increasing hypoglycemic effects → avoid concurrent use if possible; monitor and consider dose adjustments
Sulfonamides, GLP-1 RA, SGLT2 inhibitors, insulin → increased risk of hypoglycemia → monitor blood glucose and consider dose adjustments
Glipizide ADR?
Common - asthenia
Less common - hypoglycemia, nausea, headache, tremors, constipation, diarrhea, dizziness, nervousness, tremor
Rare but serious - cutaneous hypersensitivity, hemolytic anemia, hepatotoxicity, disulfiram reaction
Hydrocodone brand name and class?
Norco, Lorset, Vicodin, Hysingla ER
Opioid Analgesic. C-II
Hydrocodone common FDA label indication, dosing, and titration?
Pain, severe: adults, 12 h extended release capsule, 10 mg q12h initially, may titrate to response; 24 h extended release tablet, 20 mg po daily, may titrate to response
Hydrocodone MOA?
Hydrocodone binds to opiate receptors, resulting in altered perception of pain.
Hydrocodone box warnings?
Addiction, abuse, misuse, REMS, respiratory depression, accidental ingestion, neonatal opioid withdrawal, alcohol, CYP3A4/5 interactions, hepatotoxicity, concurrent use with benzodiazepines
Hydrocodone contraindications?
Hypersensitivity, paralytic ileus, respiratory depression, severe asthma
Hydrocodone drug interactions?
Barbiturates, benzodiazepines, centrally acting muscle relaxants, phenothiazines, hydroxyzine → additive CNS depression → avoid concurrent use with opioids
Buprenorphine, opioid mixed agonists/antagonists, opioid antagonists → precipitation of withdrawal symptoms → avoid concurrent use with opioids
CYP3A4/5 inducers → Increased hydrocodone metabolism decreases hydrocodone efficacy → Monitor and consider hydrocodone dose increase
CYP2D6 inhibitors → Decreased activation of hydrocodone to hydromorphone, decreased hydrocodone efficacy → Monitor and consider dose increases of hydrocodone
MAOIs → Additive respiratory depression and increased risk of serotonin syndrome → Avoid concurrent use
SSRIs, SNRIs, TCAs, triptans → Increased risk of serotonin syndrome → Counsel patient on signs and symptoms of serotonin syndrome (palpitations, agitation, sweating, etc.) and to seek immediate medical attention if it develops
Hydrocodone ADR?
Common - constipation, GI distress, somnolence
Less common - rash, respiratory depression, euphoria, pruritus, dizziness, chest pain
Rare but serious - Stevens-Johnson syndrome, physical dependence, tolerance, respiratory depression, serotonin syndrome, adrenal insufficiency, decreased sex hormones
Ibrandronate brand name and class?
Boniva
Class: Bisphosphonate
Ibandronate common FDA label indication, dosing, and titration?
Postmenopausal osteoporosis (treatment): 150 mg po once monthly
Postmenopausal osteoporosis (prophylaxis): 150 mg po once monthly
Ibandronate MOA?
Ibandronate binds to bone hydroxyapatite and, at the cellular level, inhibits osteoclast activity, thereby modulating bone metabolism.
Ibandronate box warnings?
None
Ibandronate contraindications?
Esophageal abnormalities, which delay esophageal emptying, hypocalcemia, inability to sit or stand upright for at least 60 min
Ibandronate drug interactions?
Aluminum, calcium-containing products → Decreased bisphosphonate absorption → Separate administration by 1-2 h
H2-blockers and PPIs → Decreased bisphosphonate absorption → Separate administration by 12-24 h
NSAIDs → Increased gastric and renal toxicity → Monitor for toxicity when used concurrently
Ibandronate ADR?
Common - Indigestion, backache, respiratory tract infections
Less common - HTN, diarrhea, abdominal pain, headache, myalgia
Rare but serious - Osteonecrosis of the jaw, esophageal cancer, esophageal ulcers, immune hypersensitivity, arrhythmia, bone fractures, severe muscle pain
Glyburide brand name and class?
Glynase
Class: Second-Generation Sulfonylurea, Antidiabetic
Glyburide common FDA label indication, dosing, and titration?
Diabetes mellitus, type II: 1.25-20 mg po daily; titrate to effect, max dose 20 mg po daily
Glyburide MOA?
Sulfonylureas enhance insulin secretion from pancreatic β-cells and potentiate insulin action on several extrahepatic tissues. Long-term sulfonylureas increase peripheral utilization of glucose, suppress hepatic gluconeogenesis, and possibly increase the sensitivity and/or number of peripheral insulin receptors.
Glyburide box warnings?
None
Glyburide contraindications?
Hypersensitivity to sulfonylureas, diabetic ketoacidosis, Type I diabetes, concurrent bosentan
Glyburide drug interactions?
Beta-blockers → Altered glucose metabolism and increased risk of hypoglycemia. Symptoms of hypoglycemia masked → Avoid propranolol, use others with caution and increased monitoring
Bosentan → Glyburide may enhance the hepatotoxic effect of bosentan. Bosentan may increase the metabolism of glyburide → Contraindicated
CYP2C9 inducers → Induction of sulfonylureas metabolism by inducers and decreased sulfonylureas levels → Monitor blood glucose and consider dose adjustments of sulfonylureas
CYP2C9 inhibitors → Inhibition of sulfonylureas metabolism by inhibitors and increased sulfonylureas levels → Monitor blood glucose and consider dose adjustments of sulfonylureas
Fluoroquinolones, NSAIDs, fenofibrate, SSRIs, somatostatin analogues → Altered glucose metabolism and increased risk of hypoglycemia and hyperglycemia → Avoid concurrent use if possible; monitor and consider dose adjustments
MAOIs → Stimulation of insulin secretion, hypoglycemic effects → Avoid concurrent use if possible; monitor and consider dose adjustments
Psyllium → Psyllium may delay absorption of glucose from meals → Avoid concurrent use if possible; monitor and consider dose adjustments
Sulfonamides → Increased risk of hypoglycemia → Monitor blood glucose and consider dose adjustments of sulfonylureas
Glyburide ADR?
Common - Nocturnal enuresis
Less common - Hypoglycemia, nausea, myalgia, skin rash, heartburn
Rare but serious - Cutaneous hypersensitivity, hemolytic anemia, disulfiram reaction